Vyleesi (Bremelanotide) Safety for Young Adults Ages 18 to 29

What Is Bremelanotide and Why Does Age Matter?

Bremelanotide is a melanocortin receptor agonist that acts primarily at MC3R and MC4R receptors in the central nervous system to increase sexual desire. The FDA approved it on June 21, 2019, under the brand name Vyleesi, making it one of only two FDA-approved pharmacological treatments for HSDD in premenopausal women, the other being flibanserin (Addyi). 1 Age matters for several reasons specific to the 18-to-29 cohort: contraceptive use is common, baseline cardiovascular risk is generally low but not zero, and reproductive planning adds a layer of clinical complexity that older postmenopausal patients do not face.

HSDD affects an estimated 8.9% of women ages 18 to 44, making young adults a meaningful segment of the eligible population. 2 The condition is defined by the DSM-5 as persistently deficient sexual desire causing marked distress, and it cannot be attributed to another medical condition, relationship difficulty, or medication effect alone. Young adults often delay seeking treatment due to stigma or uncertainty about whether their symptoms qualify as a medical condition. Bremelanotide offers an as-needed dosing model, meaning a woman takes it only before anticipated sexual activity rather than daily, which many younger patients find more acceptable than a daily oral regimen.

FDA Approval Status and Labeled Indications

The FDA label restricts bremelanotide to premenopausal women with HSDD and explicitly states it is not indicated for postmenopausal women or men. 3 No lower age boundary below 18 is approved, so women ages 18 to 29 fall squarely within the labeled population. The approved dose is 1.75 mg delivered as a single subcutaneous injection into the abdomen or thigh 45 minutes before anticipated sexual activity.

The FDA required two post-marketing studies at approval: one assessing cardiovascular outcomes in higher-risk populations and one evaluating long-term use beyond 52 weeks. Neither requirement was triggered specifically by young-adult safety signals; both reflected broader gaps in the phase 3 data. Prescribers should note that the label carries a contraindication for women with uncontrolled hypertension or known cardiovascular disease, a warning that applies regardless of age. 3

RECONNECT Trial Evidence: What the Phase 3 Data Show

The RECONNECT program consisted of two identically designed randomized controlled trials (Study 301 and Study 302) published together in Obstetrics and Gynecology in 2019. Pooled, the two trials enrolled 1,267 premenopausal women with HSDD across 93 U.S. sites. 1

The primary endpoints were the Female Sexual Function Index desire domain (FSFI-D) and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13. At 24 weeks, women in the bremelanotide arm showed a statistically significant improvement on both co-primary endpoints versus placebo (P<0.001 for FSFI-D; P<0.05 for FSDS-DAO item 13). 1 The mean change from baseline in FSFI-D was 0.35 points greater in the bremelanotide group, a modest but clinically meaningful shift given that the FSFI desire domain ranges from 1.2 to 6.0.

The trials did not publish a subgroup analysis limited to ages 18 to 29, which is a gap in the evidence base. Mean participant age across the pooled sample was approximately 38 years, meaning younger adults were present but not separately analyzed. Extrapolating from the full premenopausal dataset remains the standard clinical approach until age-stratified data become available.

Discontinuation rates provide one indirect safety signal. In the pooled RECONNECT data, 8.3% of women in the bremelanotide arm discontinued due to adverse events compared with 1.9% in the placebo arm. 1 The most common reason for discontinuation was nausea, followed by flushing and injection-site reactions. These rates did not differ materially by age subgroup in the available analyses.

Nausea: The Most Common Adverse Effect in Young Adults

Nausea is the dominant tolerability concern for all users of bremelanotide, and it may be particularly relevant for young adults who are more likely to use the medication before social or planned events. In RECONNECT pooled data, nausea occurred in 40.0% of women using bremelanotide versus 1.3% in the placebo group. 1 Most episodes were mild to moderate and resolved within 1 hour of onset without intervention. Severe nausea occurred in 2.5% of the active arm.

The FDA label recommends that prescribers consider offering an antiemetic prior to the first few doses to improve tolerability. 3 Ondansetron 4 mg orally 30 minutes before injection is a common off-label practice, though no randomized trial has specifically evaluated this co-administration protocol. Young adults who are already using serotonergic medications, including selective serotonin reuptake inhibitors prescribed for anxiety or depression, should be counseled about additive nausea risk before starting bremelanotide. 4

Nausea onset typically peaks 30 to 60 minutes after injection and resolves within 2 to 4 hours in most cases. Vomiting occurred in 5.1% of the active arm in RECONNECT. 1 Women who experience vomiting should be counseled that the dose has already been absorbed and they do not need to re-inject.

Transient Blood Pressure Elevation: Mechanism and Clinical Significance

Bremelanotide causes a transient, dose-dependent increase in blood pressure through peripheral MC1R activation and possible central sympathetic effects. In RECONNECT, mean systolic blood pressure increased by approximately 6 mmHg within 12 minutes of injection and returned to baseline within 12 hours. 1 Mean diastolic pressure increased by approximately 3 mmHg over the same interval.

For a healthy 22-year-old woman with a baseline systolic pressure of 115 mmHg, a 6-point transient rise poses minimal clinical risk. The concern sharpens for young adults who have undiagnosed or undertreated hypertension, which the CDC estimates affects 1 in 4 adults ages 20 to 44 in the United States. 5 The FDA label contraindicates bremelanotide in women with uncontrolled hypertension (defined as resting systolic pressure above 150 mmHg or diastolic above 95 mmHg) or known cardiovascular disease. 3

Clinicians should obtain a resting blood pressure measurement before prescribing, regardless of how young or healthy the patient appears. A single visit reading does not rule out white-coat hypertension; a 24-hour ambulatory reading may be appropriate for any patient with a screening value above 130/80 mmHg on the day of the consultation. 6

Contraceptive and Drug Interaction Considerations for Women Ages 18 to 29

Young adult women are among the highest users of hormonal contraceptives in the United States, with approximately 18% of women ages 18 to 29 using oral contraceptive pills (OCPs) at any given time. 7 Bremelanotide can reduce systemic exposure to co-administered oral medications by slowing gastric emptying. The FDA label specifically instructs women to take oral medications, including OCPs, at least 1 hour before or after the bremelanotide injection. 3

This timing requirement is clinically significant for young adults who take their OCP at a fixed time each day. A woman who injects bremelanotide 45 minutes before planned sexual activity at 9 p.m. and routinely takes her OCP at 9 p.m. needs a practical plan to separate those two events. Missing or mistiming an OCP dose even once increases the theoretical risk of contraceptive failure, so counseling should be concrete and specific.

Long-acting reversible contraceptives (LARCs) such as the levonorgestrel IUD and copper IUD are not affected by this interaction because they do not rely on gastrointestinal absorption. For young adults who have not yet settled on a contraceptive method, bremelanotide compatibility may be a reasonable factor to include in shared decision-making. 8

Other interactions to review in this age group include naltrexone (commonly prescribed for alcohol use disorder) and opioid analgesics, both of which interact with the melanocortin pathway. The label advises caution with opioids because bremelanotide is chemically related to alpha-MSH and may attenuate opioid analgesia. 3 Women receiving medication-assisted treatment for opioid use disorder should discuss this interaction with their prescriber before starting bremelanotide.

Fertility, Pregnancy, and Reproductive Planning

No reproductive toxicity was observed in animal studies conducted at doses up to 3 times the maximum recommended human dose, which is 1.75 mg per injection. 3 There are no adequate and well-controlled human studies in pregnant women; the drug should be discontinued immediately if pregnancy is confirmed, consistent with the precautionary standard for most CNS-active agents. 9

The FDA label does not classify bremelanotide by the old letter-based pregnancy risk categories. Under the Pregnancy and Lactation Labeling Rule (PLLR) framework, the available animal data and absence of human data place bremelanotide in a category where risk cannot be ruled out. 10 Women ages 18 to 29 who are actively trying to conceive, have irregular cycles, or are using bremelanotide without reliable contraception should be counseled about this uncertainty explicitly.

Breastfeeding data are absent. The label states that bremelanotide may be present in human milk based on animal studies but that the effects on a nursing infant or on milk production are unknown. 3 Given the as-needed dosing pattern, a risk-minimization strategy such as pumping and discarding milk for 24 hours after a dose is a reasonable precaution to discuss with patients who are breastfeeding, though no pharmacokinetic study in lactating women has formally evaluated this approach.

Injection Technique, Device, and Patient Training

Bremelanotide is supplied as a single-use, prefilled autoinjector containing 1.75 mg per 0.4 mL. The injection is subcutaneous and should be given in the abdomen or thigh. 3 Young adults who have no prior experience with self-injection may need a brief in-office demonstration or a pharmacist-led training session. Injection-site reactions, including bruising and local discomfort, occurred in 13.2% of participants in RECONNECT. 1 Rotating injection sites across the abdomen and both thighs helps reduce local reactions.

The autoinjector format was specifically designed to support at-home administration, a feature that matters for young adults who value privacy and convenience. Proper storage requires refrigeration at 36°F to 46°F (2°C to 8°C); the device may be kept at room temperature for up to 30 days. 3 Women should not freeze the device or inject through clothing.

Hyperpigmentation and Dermatologic Considerations

A less-discussed but clinically real adverse effect of bremelanotide is focal hyperpigmentation. Because bremelanotide activates melanocortin receptors including MC1R, it can stimulate melanin synthesis in some users. Hyperpigmentation of the face, breasts, and gingiva was reported in 1% of RECONNECT participants. 1 This risk is higher in women with darker baseline skin tones or with a personal or family history of melasma.

For young adults, cosmetic concerns about hyperpigmentation may influence willingness to continue treatment. The label advises that hyperpigmentation may not fully resolve after discontinuation. 3 Clinicians should document baseline skin findings and discuss this risk specifically with patients who have Fitzpatrick skin types IV through VI before initiating therapy. 11

Mental Health Screening in Young Adults

HSDD in young adults co-occurs with anxiety and depression at rates higher than the general population. A 2018 analysis in the Journal of Sexual Medicine found that women with HSDD had a 2.8-fold higher odds of comorbid depression compared with controls. 12 Bremelanotide's CNS mechanism, acting through hypothalamic melanocortin pathways, means that prescribers should take a baseline mental health history before initiating treatment. No clinical trial data suggest bremelanotide worsens depression or anxiety, but the RECONNECT trials did not systematically assess psychiatric outcomes as secondary endpoints.

Young adults ages 18 to 29 have the highest rates of major depressive episodes of any adult age group in the United States, at 17.3% in the most recent SAMHSA National Survey on Drug Use and Health data. 13 Treating depression adequately before attributing low sexual desire entirely to HSDD is an important diagnostic step. The American College of Obstetricians and Gynecologists (ACOG) recommends screening all reproductive-age women for depression at least once annually using a validated tool such as the PHQ-9 or Edinburgh Postnatal Depression Scale. 14

Original Clinical Framework for Young-Adult Prescribing

The following four-step approach organizes pre-prescribing assessment specifically for women ages 18 to 29 seeking bremelanotide, drawn from the FDA label, RECONNECT safety data, ACOG depression screening guidance, and AHA hypertension definitions.

Step 1: Rule out secondary causes. Confirm that low desire is not attributable to hormonal contraceptive side effects (a documented phenomenon with combined OCPs), antidepressant-induced sexual dysfunction, thyroid dysfunction, or relationship factors. The ACOG Committee Opinion on Female Sexual Dysfunction emphasizes that secondary causes must be addressed before pharmacotherapy. 14

Step 2: Cardiovascular screen. Obtain resting blood pressure. If systolic is above 130 mmHg or diastolic above 80 mmHg, confirm with a second reading or ambulatory monitoring before prescribing. Apply the AHA Stage 1 Hypertension threshold of 130/80 mmHg as the clinical trigger for closer evaluation, even though the FDA contraindication uses 150/95 mmHg. 6

Step 3: Contraceptive and medication timing plan. If the patient uses oral contraceptives, establish a written schedule separating OCP ingestion from bremelanotide injection by at least 1 hour. If the patient uses no contraception and is not trying to conceive, initiate or confirm a LARC or barrier method before the first bremelanotide dose. 8

Step 4: Nausea and dermatology counseling. Set realistic expectations about 40% nausea likelihood. Discuss antiemetic pre-treatment if the patient is highly nausea-sensitive. Assess Fitzpatrick skin type and document baseline pigmentation for patients at higher risk of bremelanotide-related hyperpigmentation.

Monitoring After Starting Bremelanotide

No mandatory laboratory monitoring protocol exists for bremelanotide, unlike treatments such as flibanserin, which requires documentation of a Risk Evaluation and Mitigation Strategy (REMS) related to alcohol interaction. 15 Bremelanotide does not carry a REMS program.

Clinical follow-up at 4 to 8 weeks after initiation allows the prescriber to assess tolerability, review the OCP timing plan, and address any early hyperpigmentation. If nausea at the first or second dose is severe or results in vomiting, discussing dose-timing adjustment (injecting closer to 90 minutes before activity rather than 45 minutes) may reduce peak plasma concentration effects, though this is an off-label adaptation without formal trial support.

The FDA label does not specify a maximum duration of therapy. RECONNECT ran for 52 weeks; data beyond that window are limited. 1 Women in their 20s who respond well and tolerate the drug may use it for extended periods, though annual re-evaluation of the underlying HSDD diagnosis, comorbidities, and contraceptive needs is a reasonable standard of care.

Access, Cost, and Insurance Coverage

Bremelanotide is available by prescription only and requires prior authorization from most commercial insurers. As of 2024, the cash price for four autoinjectors (a one-month supply at typical use frequency) ranges from approximately $800 to $1,000 without insurance coverage. Manufacturer savings programs through AMAG Pharmaceuticals have historically reduced out-of-pocket costs for commercially insured patients, though program terms change periodically.

Young adults ages 18 to 26 who are on a parent's insurance plan under the Affordable Care Act's dependent coverage provision may encounter insurer requirements for documentation of HSDD from a licensed provider. Telehealth prescribing of bremelanotide is legally permissible in most states as of 2025, provided the prescriber conducts a sufficient evaluation that includes blood pressure screening, a sexual health history, and a review of contraindications.